{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:18:53Z","timestamp":1781119133735,"version":"3.54.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AI42269"],"award-info":[{"award-number":["RO1 AI42269"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AI148161"],"award-info":[{"award-number":["RO1 AI148161"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16810055"],"award-info":[{"award-number":["16810055"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clim.2021.108680","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T03:32:34Z","timestamp":1611372754000},"page":"108680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis"],"prefix":"10.1016","volume":"225","author":[{"given":"Tomohiro","family":"Koga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2021.108680_bb0005","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2021.108680_bb0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2021.108680_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0020","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/art.24572","article-title":"Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important","volume":"60","author":"Lundstrom","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2018.04.001","article-title":"Cytokine targeting in rheumatoid arthritis","volume":"206","author":"Bui","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/ard.49.6.363","article-title":"Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients","volume":"49","author":"Reilly","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","article-title":"Managing rheumatic and musculoskeletal diseases - past, present and future","volume":"13","author":"Burmester","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2021.108680_bb0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0050","first-page":"463","article-title":"Synovial tissue research: a state-of-the-art review, Nature reviews","volume":"13","author":"Orr","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2021.108680_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0889-857X(05)70206-4","article-title":"Pathogenesis of rheumatoid arthritis: the role of synoviocytes","volume":"27","author":"Yamanishi","year":"2001","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.clim.2021.108680_bb0060","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/art.20260","article-title":"Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis","volume":"50","author":"Benito","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0065","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2741\/1399","article-title":"Synovial activation in rheumatoid arthritis","volume":"9","author":"Ospelt","year":"2004","journal-title":"Front. Biosci."},{"key":"10.1016\/j.clim.2021.108680_bb0070","doi-asserted-by":"crossref","first-page":"108579","DOI":"10.1016\/j.clim.2020.108579","article-title":"Up-regulated DERL3 in fibroblast-like synoviocytes exacerbates inflammation of rheumatoid arthritis","volume":"220","author":"Geng","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.febslet.2008.01.022","article-title":"Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes","volume":"582","author":"Koga","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.clim.2021.108680_bb0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/rheumatology\/kep089","article-title":"Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes","volume":"48","author":"Migita","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2021.108680_bb0085","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2021.108680_bb0090","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0095","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"Lliso-Ribera","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0100","doi-asserted-by":"crossref","first-page":"108342","DOI":"10.1016\/j.clim.2020.108342","article-title":"Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: new insights into B-cell activation","volume":"211","author":"Davis","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/ard.51.9.1029","article-title":"Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study","volume":"51","author":"van Zeben","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175281","article-title":"Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan","volume":"12","author":"Koga","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2021.108680_bb0115","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.1114465108","article-title":"Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage","volume":"108","author":"Shi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2021.108680_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102163","article-title":"Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis","volume":"9","author":"Stoop","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2021.108680_bb0125","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clim.2021.108680_bb0130","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0135","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","article-title":"Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study","volume":"71","author":"Gomez-Reino","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0145","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0150","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard.2003.017574","article-title":"Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations","volume":"63","author":"De Rycke","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","article-title":"The B cell response to citrullinated antigens in the development of rheumatoid arthritis","volume":"14","author":"Scherer","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2021.108680_bb0160","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.4049\/jimmunol.166.6.4177","article-title":"The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin","volume":"166","author":"Masson-Bessiere","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0165","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/art.21220","article-title":"Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/ard.2005.044743","article-title":"Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids","volume":"65","author":"Takizawa","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clim.2018.12.004","article-title":"The role of synthetic manufactured peptides containing common citrullinated epitopes in rheumatoid arthritis diagnosis","volume":"199","author":"Darawshe","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2019.01.001","article-title":"High levels of antibodies to citrullinated alpha-enolase peptide-1 (CEP-1) identify erosions and interstitial lung disease (ILD) in a Chinese rheumatoid arthritis cohort","volume":"200","author":"Liu","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/1529-0131(200101)44:1<41::AID-ANR6>3.0.CO;2-0","article-title":"Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis","volume":"44","author":"Reparon-Schuijt","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","volume":"39","author":"Derksen","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.clim.2021.108680_bb0195","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.34344","article-title":"Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?","volume":"64","author":"Demoruelle","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0200","first-page":"517","article-title":"Lung consolidation and mediastinal lymphadenopathy in patients with early anti-citrullinated protein antibody-positive rheumatoid arthritis","volume":"37","author":"Endo","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2021.108680_bb0205","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1056\/NEJMp048114","article-title":"B cells, be gone--B-cell depletion in the treatment of rheumatoid arthritis","volume":"350","author":"Tsokos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","article-title":"From T to B and back again: positive feedback in systemic autoimmune disease","volume":"1","author":"Shlomchik","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0215","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0220","doi-asserted-by":"crossref","first-page":"108360","DOI":"10.1016\/j.clim.2020.108360","article-title":"B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF-alpha production","volume":"212","author":"Elliott","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clim.2021.108680_bb0230","doi-asserted-by":"crossref","first-page":"925135","DOI":"10.1155\/2012\/925135","article-title":"CD4(+)T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0235","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","article-title":"Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2021.108680_bb0240","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3899\/jrheum.150117","article-title":"Efficacy and safety of subcutaneous and intravenous loading dose regimens of Secukinumab in patients with active rheumatoid arthritis: results from a randomized phase II study","volume":"43","author":"Tlustochowicz","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2021.108680_bb0250","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/03009742.2017.1390605","article-title":"Secukinumab after anti-tumour necrosis factor-alpha therapy: a phase III study in active rheumatoid arthritis","volume":"47","author":"Dokoupilova","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.clim.2021.108680_bb0255","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0260","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"investigators, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2021.108680_bb0265","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0270","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2021.108680_bb0275","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0280","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0285","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2021.108680_bb0290","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/clim.2001.5093","article-title":"Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity?","volume":"100","author":"Sporici","year":"2001","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0295","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0952-7915(92)90075-P","article-title":"Costimulation of T-cell growth","volume":"4","author":"Liu","year":"1992","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0300","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.clim.2021.108680_bb0305","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4049\/jimmunol.165.3.1352","article-title":"CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression","volume":"165","author":"Carreno","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0310","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.1780390115","article-title":"The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium","volume":"39","author":"Liu","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0315","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI119781","article-title":"Functional CD40 ligand is expressed by T cells in rheumatoid arthritis","volume":"100","author":"MacDonald","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2021.108680_bb0320","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0325","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000345","article-title":"Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study","volume":"3","author":"Alten","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.clim.2021.108680_bb0335","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1073\/pnas.1710437115","article-title":"Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor","volume":"115","author":"Peled","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2021.108680_bb0340","doi-asserted-by":"crossref","first-page":"108485","DOI":"10.1016\/j.clim.2020.108485","article-title":"SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes","volume":"217","author":"Sandigursky","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0345","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coi.2017.04.010","article-title":"Metabolic signatures of T-cells and macrophages in rheumatoid arthritis","volume":"46","author":"Weyand","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1483","article-title":"Glucose transporter 1 in rheumatoid arthritis and autoimmunity","volume":"12","author":"Zezina","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.clim.2021.108680_bb0360","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13075-019-1865-3","article-title":"Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis","volume":"21","author":"Song","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2021.108680_bb0365","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3389\/fimmu.2019.00833","article-title":"Targeting T cell activation and lupus autoimmune phenotypes by inhibiting glucose transporters","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0370","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41591-018-0003-0","article-title":"Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2021.108680_bb0375","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/art.40790","article-title":"The contribution of PTPN22 to Rheumatic Disease","volume":"71","author":"Mustelin","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0380","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.4049\/jimmunol.1200150","article-title":"PTPN22 alters the development of regulatory T cells in the thymus","volume":"188","author":"Maine","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0385","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/eji.201747092","article-title":"Protein tyrosine phosphatase PTPN22 regulates IL-1beta dependent Th17 responses by modulating dectin-1 signaling in mice","volume":"48","author":"Purvis","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0390","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/ard.2005.050385","article-title":"Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment","volume":"65","author":"Walker","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108680_bb0395","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2021.108680_bb0400","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/01.tp.0000177643.05739.cd","article-title":"Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts","volume":"80","author":"Paniagua","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108680_bb0405","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clim.2021.108680_bb0410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0415","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/art.21243","article-title":"Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor","volume":"52","author":"Siegel","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108680_bb0420","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2021.108680_bb0425","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3899\/jrheum.101362","article-title":"Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium","volume":"38","author":"Migita","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2021.108680_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2021.108680_bb0435","doi-asserted-by":"crossref","first-page":"108592","DOI":"10.1016\/j.clim.2020.108592","article-title":"Clinical markers combined with HMGB1 polymorphisms to predict efficacy of conventional DMARDs in rheumatoid arthritis patients","volume":"221","author":"Xu","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108680_bb0440","first-page":"811","article-title":"Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population","volume":"29","author":"Koga","year":"2011","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:43:39Z","timestamp":1778816619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661621000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":88,"alternative-id":["S1521661621000176"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108680","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108680"}}